Inactivation of beta1 integrin induces proteasomal degradation of Myc oncoproteins

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• The MYC family of oncogenes (MYC, MYCN, MYCL) are implicated in numerous human cancers.
• MYCN amplification and N-Myc overexpression are key drivers and risk factors in neuroblastoma.
• Fibronectin-derived peptide FNIII14 was previously shown to functionally inactivate β1-integrins.

Purpose of the Study:

• To investigate the effect of β1-integrin inactivation by FNIII14 on N-Myc in neuroblastoma cells.
• To evaluate the therapeutic potential of FNIII14 in preclinical models of neuroblastoma and other Myc-driven cancers.

Main Methods:

• Treatment of neuroblastoma cells with MYCN amplification with FNIII14.
• Assessment of N-Myc protein levels via proteasomal degradation.
• Evaluation of cancer cell malignant properties (proliferation, migration).
• In vivo studies using a mouse xenograft model.

Main Results:

• FNIII14-induced β1-integrin inactivation led to proteasomal degradation of N-Myc in neuroblastoma cells.
• N-Myc degradation reduced anchorage-independent proliferation and invasive migration.
• FNIII14 administration inhibited tumor growth in a mouse xenograft model, with decreased N-Myc levels.
• The mechanism was also effective against c-myc in pancreatic cancer cells.

Conclusions:

• β1-integrin inactivation is a novel strategy for targeting Myc oncoproteins in cancer.
• FNIII14 demonstrates potential as a therapeutic agent for Myc-driven cancers, including neuroblastoma and pancreatic cancer.